China’s Ministry of Foreign Affairs said it has informed the embassies of relevant countries in Beijing about foreign nationals affected by a debris flow in Gyirong, Tibet. The ministry said details are still being verified and it will maintain commu

Individual Stock News 1. Bilibili-W (09626.HK) released its interim results: net profit of RMB 541 million, an increase of 160.65% year-on-year. 2. Shenghong Technology (02476.HK) released its interim results: net profit attributable to shareholders of RMB 2.857 billion, an increase of 33.3% year-on-year. 3. Fosun International (00656.HK) released its interim results: net profit attributable to shareholders of RMB 1.721 billion, an increase of 160.3% year-on-year. 4. China Communications Construction (01800.HK) released its interim results: net profit of RMB 9.554 billion, a decrease of 25.75% year-on-year. 5. China Pacific Insurance (02601.HK) released its interim results: net profit attributable to shareholders of RMB 30.775 billion, an increase of 10.4% year-on-year. 6. Zoomlion (01157.HK) released its interim results: profit attributable to shareholders of RMB 2.102 billion, a decrease of 23.65% year-on-year. 7. China Life Insurance (02628.HK) released its interim results: net profit attributable to shareholders was RMB 134.489 billion, an increase of 228.6% year-on-year. 8. Biocytogen-B (02315.HK) released its interim results: profit attributable to shareholders was RMB 241 million, an increase of 402.3% year-on-year. 9. Tianqi Lithium (09696.HK) released its interim results: profit attributable to shareholders was RMB 4.236 billion, an increase of 4788.84% year-on-year. 10. Li Ning (02331.HK): granted a total of 12.6065 million share options. 11. Insilicon Technologies (03696.HK): proposed to issue US$305 million zero-coupon convertible bonds due in 2027. 12. WoAn Robotics (6600.HK): Revenue in Europe and the US increased by approximately 93% year-on-year, with three new products, including a humanoid home robot, contributing 65.4% of the revenue increase. 13. CanSino Biologics (06185.HK): In the first half of 2026, the company achieved operating revenue of approximately RMB 550 million, a year-on-year increase of 43.8%; the net loss attributable to the parent company narrowed significantly year-on-year.

China A-share biologics sector slipped intraday; Sanyuan Gene, Watson Bio, CanSino Biologics, Kanghua Bio and Zhifei Biological declined.